Elan Corporation turnaround / James B. Shein, Robert Anstey & Nathan Lang.

Format:

Book

Author/Creator:

Shein, James B., 1942- author.

Anstey, Robert, author.

Lang, Nathan, author.

Series:

SAGE knowledge. Cases.

SAGE Knowledge. Cases.

SAGE knowledge. Cases

Language:

English

Subjects (All):

Elan Corporation.

Corporate turnarounds--Case studies.

Corporate turnarounds.

Corporations--Finance--Case studies.

Corporations.

Corporations--Finance.

Corporate governance.

Corporate governance--Case studies.

Genre:

Case studies.

Physical Description:

1 online resource : illustrations (black and white, and colour).

Place of Publication:

[London] : SAGE, 2016.

System Details:

text file

Summary:

The case begins with newly appointed chairman and interim CEO Garo Armen dwelling on the significant issues that Elan Corporation, an Irish pharmaceutical company, faces. Its share price has plummeted 96% after accusations of accounting fraud and the discontinuation of an important clinical trial due to the drug's severe side effects. As a result, Elan faces insolvency. About $2 billion in debt that could no longer be satisfied in stock will soon mature, and there are questions regarding the company's structure and various operating concerns.

Notes:

Originally Published in: Shein, J., Anstey, R., & Lang, N. (2010). Elan Corporation Turnaround. 5-210-262. Evanston, IL: Kellogg School of Management, Northwestern University.

No ILL or scholarly sharing allowed.

Description based on online resource; title from home page (viewed on April 28, 2016).

ISBN:

9781473969995

OCLC:

1017713158

Access Restriction:

Restricted for use by site license.